KB 001 - Keystone Bio
Alternative Names: KB-001 - Keystone Bio; KB-001 MabLatest Information Update: 28 Aug 2024
At a glance
- Originator Keystone Bio
- Class Anti-inflammatories; Antibacterials; Monoclonal antibodies
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Periodontal disorders
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for clinical-Phase-Unknown development in Periodontal-disorders(Prevention) in USA (PO)
- 26 Jul 2021 Interim immunogenicity data from a clinical trial in periodontal disorders presented at the Alzheimer's Association International Conference 2021 (AAIC-2021)
- 26 Jul 2021 Pharmacodynamics data from a preclinical trial in periodontal disorders presented at the Alzheimer's Association International Conference 2021 (AAIC-2021)